Last reviewed · How we verify
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma (ATPase)
This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.
Details
| Lead sponsor | Hunan Province Tumor Hospital |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 90 |
| Start date | Sat Nov 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Aug 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Non-small Cell Lung Cancer
Interventions
- Crizotinib
Countries
China